Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oxaliplatin and Capecitabine in Advanced Esophageal and Gastric Adenocarcinoma
NCT00040859Phase 2Completed
- Sponsor
- Cancer and Leukemia Group B
- Start
- Sep 2002
- Primary completion
- Jan 2005
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of oxaliplatin, capecitabine in esophageal adenocarcinoma (EAC), gastroesophageal junction adenocarcinoma, gastric adenocarcinoma, sponsored by Cancer and Leukemia Group B. Started Sep 2002; status: completed.
02
Drugs
oxaliplatincapecitabine
03
Conditions
esophageal adenocarcinoma (EAC)gastroesophageal junction adenocarcinomagastric adenocarcinoma
Beyond the preview
Go deeper on NCT00040859.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00040859.